首页> 外文期刊>Journal of hepato-biliary-pancreatic sciences >Surgical treatment of lymph node metastases from hepatocellular carcinoma.
【24h】

Surgical treatment of lymph node metastases from hepatocellular carcinoma.

机译:肝细胞癌淋巴结转移的外科治疗。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

BACKGROUND: No consensus has been reached on the feasibility and efficacy of surgery for lymph node metastases (LNM) from hepatocellular carcinoma (HCC). METHODS: Of 2189 patients with HCC treated at our hospital between July 1992 and March 2008, we retrospectively reviewed the medical dossiers of the 18 patients (0.8%) who underwent lymph node resection and were pathologically diagnosed to have LNM from HCC. The surgical procedure for LNM was selective lymphadenectomy of those lymph nodes suspected to harbor metastasis. The feasibility and efficacy of selective lymphadenectomy was examined, and clinicopathological factors were analyzed with the aim of determining which patients would most benefit from surgery. RESULTS: Eighteen patients underwent surgery without mortality or liver failure. Morbidities were found in four patients (22.2%). The median survival time (MST) after surgery was 29 months [95% confidence interval (CI) 21-38 months). The 1-, 3-, and 5-year overall survival rates were 85, 42, 21%. The median progression-free survival (PFS) after surgery was 6 months (95% CI 1-11 months), and the median extrahepatic PFS was 16 months (95% CI 13-18 months). Single LNM was the only favorable prognostic factor after surgery (Hazard ratio 0.082, 95% CI 0.008-0.83). CONCLUSION: Selective lymphadenectomy of LNM from HCC was a feasible and efficacious procedure. Survival rates can be expected to improve after selective lymphadenectomy of single LNM.
机译:背景:关于肝细胞癌(HCC)淋巴结转移(LNM)手术的可行性和有效性尚未达成共识。方法:回顾性分析了1992年7月至2008年3月在我院接受治疗的2189例HCC患者中18例(0.8%)接受了淋巴结切除并经病理学诊断为HCC LNM的患者的临床资料。 LNM的外科手术是对那些怀疑有转移的淋巴结进行选择性淋巴结清扫术。检查了选择性淋巴结清扫术的可行性和有效性,并分析了临床病理因素,目的是确定哪些患者将从手术中受益最大。结果:18例患者接受了手术而没有死亡或肝功能衰竭。在四名患者中发现了发病率(22.2%)。手术后中位生存时间(MST)为29个月[95%置信区间(CI)为21-38个月]。 1年,3年和5年总生存率分别为85%,42%和21%。手术后中位无进展生存期(PFS)为6个月(95%CI 1-11个月),肝外PFS中位为16个月(95%CI 13-18个月)。单一LNM是术后唯一的有利预后因素(危险比0.082,95%CI 0.008-0.83)。结论:肝癌LNM选择性淋巴结清扫术是一种可行,有效的方法。单个LNM选择性淋巴结清扫术后,存活率有望提高。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号